EMA grants orphan drug status to multiple myeloma treatment
- Triphase Accelerator has received orphan drug status from EMA. FDA has already granted orphan drug status to marizomib.
- Marizomib is a proteasome inhibitor that targets all the proteasome subunits, which allows more durable and sustained responses.
- Triphase is developing intravenous and oral formulations of marizomib.
According to the American Cancer Society, there will be 24,050 new cases of multiple myeloma diagnosed this year and 11,090 deaths. In general, although multiple myeloma responds well to initial treatment, it almost always returns. There truly is an unmet medical need associated with this disease.
Frank Stonebanks, Founder and CEO of Triphase, said, “We are committed to developing this promising agent through proof-of-concept to fill an unmet medical need for patients with relapsed and refractory multiple myeloma, an often fatal hematologic cancer for which new treatment options are needed.”
- Pharmaceutical Business Review EMA committee recommends orphan drug status to Triphase's myeloma drug marizomib